Gene therapy projects for LGMDs developed by Atamyo Therapeutics (LGMD2I/R9, LGMD2A/R1, LGMD2B/R2, LGMD2C/R5, LGMD2D/R3).
The webinar will be held in english by Prof. Isabelle Richard.
To register to the GFB patient register, simply fill in the registration form in all its fields.
It is availble from Monday to Friday, from 9 am to 12 pm.
Any amount you donate to the Research Fund will be a real help in the fight against Beta-sarcoglycanopathies and other forms of muscular dystrophy.
Sign up to the GFB Newletter
In total, the GFB now counts 696 patients affected by sarcoglycanopathy, divided according to the following table:
On the GFB Onlus page you can consult the distribution of patients in Italy and abroad.